Viewing Study NCT00095459


Ignite Creation Date: 2025-12-24 @ 3:02 PM
Ignite Modification Date: 2026-01-29 @ 1:43 PM
Study NCT ID: NCT00095459
Status: COMPLETED
Last Update Posted: 2019-12-17
First Post: 2004-11-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module References Module